Table 1 Patient characteristics, N = 88
Characteristic | Patients |
|---|---|
Sex | |
• Male | 57 (64.8%) |
• Female | 31 (35.2%) |
Median Age [y] | 51.0 (18 – 73) |
• < 50 | 39 (44.3%) |
• ≥ 50 | 49 (55.7%) |
Median KPS | 80 (40 – 100) |
• KPS < 70 | 18 (20.5%) |
• KPS ≥ 70 | 65 (73.9%) |
• Unknown | 5 (5.7%) |
Median dose of primary radiotherapy | 60 Gy |
Median dose of re-irradiation | 36 Gy |
Time interval ≤ 12 months | 29 (33%) |
Time interval > 12 months | 59 (67%) |
Bevacizumab during re-irradiation | |
• Yes | 71 (80.7%) |
• No | 17 (19.3%) |
MGMT methylation status | |
• Methylated | 42 (47.7%) |
• not methylated | 36 (40.9%) |
• unknown | 10 (11.4%) |
Initial WHO grade | |
• II | 7 (8.0%) |
• III | 20 (22.7%) |
• IV | 61 (69.3%) |
WHO grade at relapse | |
• III | 23 (26.1%) |
• IV | 65 (73.9%) |
Concomitant TMZ treatment during first RT | |
• Yes | 68 (77.3%) |
• No | 20 (22.7%) |
Chemotherapy | |
• No adjuvant chemotherapy | 36 (40.9%) |
• Adjuvant therapy | 45 (51.1%) |
• Unknown | 7 (8.0%) |